Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

No reported Deferred Revenue figures are available to summarize.

Deferred Revenue history

Currency unavailable · from the balance sheet

No Deferred Revenue data reported for this period type.

Deferred Revenue vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Deferred Revenue for KARD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RNAAtrium Therapeutics, Inc.Mar 2026$9.34M USD——3.2%
TNYATenaya Therapeutics, Inc.Mar 2026$5.72M USD——4.2%
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$2.8M USD——0.4%
CYTKCytokinetics, IncorporatedJun 2026$1.65M USD+23.0%—0.1%
IKTInhibikase Therapeutics, Inc.Mar 2026$0 USD——0.0%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+23.0%—0.4%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.